A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

Inclusion Criteria: * Pathology diagnosis of breast cancer,Chemotherapy naïve * ECOG performance status 0-1 * Age 18 to 70 years * Available for at least 2 cycles of consistent neoadjuvant/adjuvant therapy * White blood cell ≥ 4.0×109/L; absolute neutrophil count ≥2.0 × 109/L; platelet count ≥ 100 × 109/L * Alanine aminotransferase ≤1.5×ULN; aspartate aminotransferase ≤1.5×ULN; serum creatinine ≤1.5×ULN * No obvious cardiac dysfunction Exclusion Criteria: * Prior bone marrow or stem cell transplantation * Received systemic antibiotics treatment within 72 h of chemotherapy * Other disease might have influence on bone marrow function * Radiation therapy within 4 weeks of randomization into this study * Previous exposure or or allergic to Pegylated rhG-CSF * Pregnancy, lactation